GLP-1 receptor agonists
MACE-outcome trials of semaglutide and dulaglutide in T2DM.
- Trials
- 2
- Years
- 2016–2019
Sort
- 2019REWINDPrimary CV preventionIn 9,901 patients with T2DM mostly without established CV disease, dulaglutide 1.5 mg weekly reduced CV death, non-fatal MI or non-fatal stroke compared with placebo.HR 0.88Read →
- 2016SUSTAIN-6CV outcome trialIn 3,297 patients with T2DM at high CV risk, subcutaneous semaglutide 0.5 or 1.0 mg weekly reduced CV death, non-fatal MI or non-fatal stroke versus placebo.HR 0.74Read →